O
DNTH icon

OrbiMed’s Dianthus Therapeutics DNTH Stock Holding History

OrbiMed’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-140,685
Closed -$3.17K – 119
2022
Q3 		$3.17K Hold
140,685
– – 0.06% 114
2022
Q2 		$2.7K Hold
140,685
– – 0.05% 124
2022
Q1 		$6.53M Hold
140,685
– – 0.11% 112
2021
Q4 		$9.97M Buy
140,685
+22,375
+19% +$2.25M 0.13% 115
2021
Q3 		$13.8M Sell
118,310
-8,800
-7% -$1.03M 0.15% 114
2021
Q2 		$19.9M Buy
127,110
+67,794
+114% +$12.5M 0.2% 99
2021
Q1 		$11.2M Buy
+59,316
New +$9.98M 0.11% 118

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed's DNTH Position: Q4 2022 in Review

OrbiMed sold out of Dianthus Therapeutics (DNTH) in Q4 2022, closing a stake of 140,685 shares — an estimated $3.17K sold.

OrbiMed first reported a position in DNTH in Q1 2021 and held it in 7 quarters. The position peaked at $19.9M in Q2 2021. 53 funds tracked by Wall St. Rank hold DNTH as of Q4 2022.

  • OrbiMed reported no remaining Dianthus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • OrbiMed sold 140,685 Dianthus Therapeutics shares in Q4 2022, an estimated $3.17K.
  • OrbiMed first reported a position in Dianthus Therapeutics in Q1 2021 and held it in 7 quarters.
  • OrbiMed's Dianthus Therapeutics position peaked at $19.9M in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2022.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.